COMMUNIQUÉS West-GlobeNewswire

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
17/07/2024
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on [...]
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
17/07/2024
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s [...]
CervoMed to Participate in the Emerging Growth Conference
17/07/2024
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will [...]
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
17/07/2024
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- [...]
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
17/07/2024
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. ( [...]
HealthLynked Expands Telemedicine Nationwide
17/07/2024
NAPLES, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. ( OTCQB: HLYK ), a global leader in healthcare network technology, today announced a strategic partnership with national telemedicine provider [...]
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
17/07/2024
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30 [...]
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
17/07/2024
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal
17/07/2024
Study published in Journal of Cosmetic and Laser Therapy highlights the TheraClear ® X photopneumatic device as an effective treatment option, either as monotherapy or in combination with topical or oral treatments, for [...]
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
17/07/2024
– FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease after Regenerative [...]
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
17/07/2024
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage [...]
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
17/07/2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology [...]
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17/07/2024
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent [...]
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
17/07/2024
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited [...]
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17/07/2024
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent [...]
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
16/07/2024
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and [...]
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
16/07/2024
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
16/07/2024
AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the [...]
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements
16/07/2024
Reaffirms commitment to regaining compliance with the NYSE American continued listing standards MINNEAPOLIS, MN, July 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), [...]

Pages